What factors affect Humira dosing?
Humira® is a medicine used to treat a wide range of autoimmune diseases or a disease caused by its own body immune system by mistake of attack on their own cells. Humira®, which was also sold as a generic medicine Adalimumab, has been subjected to increasing control since its initial approval by food management and drug administrations for the treatment of rheumatoid arthritis. There are serious concerns that the use of drugs Humira® and other factor of necrosis of tumor necrosis can cause hepatosplenic lymphoma T-cell-rare and usually a fatal form of leukemia-U children treated with autoimmune disorders. Since then, these drugs have been given a black box warning, alert patients and prescribers that they increase the risk of serious bacterial, fungal, mycobacterial, viral and parasitic infections in multiple organ systems that can lead to hospitalization or death. Thanks to these very real risks, it is important to consider factorye age, weight and condition of the patient to determine the lowest effectHumira® dosage.
Standard dose of Humira® for polyarticular juvenile idiopathic arthritis is calculated primarily based on weight. In patients aged four and 17 years, weighing more than £ 66 (30 kg), Humira® dosing should be used every two weeks. Pediatric patients who weigh between £ 33 (15 kg) and £ 66 (30 kg) should receive 20 mg Humira® every two weeks. While the drugs were used for patients weighing less than £ 33 (15 kg), there is insufficient data to be recommended. The Humira® dose is the same in patients who receive a medicine as monotherapy, and in patients who receive non -steroidal anti -inflammatory drugs, glucocorticoids or other analgesics.
in adult patients, tandard Humira® eating for psoriatic arthritis, rheumatoid arthritis or ankylosing spondylitis is the same as in pediatric patients weighing morethan £ 66 (30 kg): 40 mg injections served every two weeks. Patients receiving medicines together with other pain controls and inflammation do not require adjustments to their dosage. However, those who do not receive methotrexate can benefit from increasing Humira® to one injection per week.
patients who have decided to use medicines for Crohn's disease should receive an initial breakthrough dose of 160 mg, which is given as four injections 40 mg per day or two 40 mg injection in two consecutive days. After 14 days, two injections of 40 mg should be administered. Another 14 days after this dose should start standard maintenance regime 40 mg, followed by 40 mg doses administered every 14 days. The safety of this regime for the treatment of Crohn's disease has not been evaluated for a long time for a long time than one year.
Humira® safety for the treatment of plaque psoriasis was not evaluated for more than one year. As with Crohn's disease, the initial breakthrough dose is recommended. On the first day of treatment would mTwo injections of 40 mg could be administered. After 14 days, a standard dose mode for adult maintenance should be used for 40 mg every two weeks.